ArticleCurrent medical science2026
A Novel Nomogram for Predicting Meningioma Grade Based on Radiomics Features and Clinical Characteristics.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to develop a predictive model utilizing radiomics features and clinical characteristics to accurately differentiate low-grade (WHO grade I) from high-grade (WHO grade II/III) meningiomas preoperatively, thereby improving treatment planning and prognosis.
methodsA retrospective analysis of 288 meningioma cases (191 low-grade and 97 high-grade) confirmed by histopathology was conducted. Radiomics features were extracted from contrast-enhanced T1-weighted MRI (CE-T1WI) using the pyradiomics package, followed by feature selection via LASSO regression. Predictive models (logistic regression, decision tree, support vector machine [SVM], adaptive boosting) were evaluated. Clinical variables (peritumoral edema index and monocyte count) were integrated to try to improve the predictive performance. Model efficacy was assessed using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis.
resultsFour key radiomics features were identified as significant discriminators of tumor grade. The logistic regression model demonstrated superior predictive performance over decision trees, SVMs, and adaptive boosting methods. The inclusion of the peritumoral edema index and monocyte count increased the AUC to 0.801 (95% CI 0.753-0.869) in the training set. However, in the validation set, the radiomics model achieved the best performance, with an AUC of 0.770 (95% CI 0.670-0.869).
conclusionsThe radiomics-based model effectively predicts high-grade meningioma and demonstrates superior performance compared to the clinical and combined models. This study advances the precision of meningioma grading, offering significant implications for treatment planning and patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.